Juvenile myelomonocytic leukemia

Section editor transclusions

1 regimens on this page 1 variants on this page

First-line therapy

Azacitidine monotherapy

Regimen

Study	Years of enrollment	Evidence
Niemeyer et al. 2021 (AZA-JMML-001)	2015-2017	Phase 2, <20 pts (RT)

Chemotherapy

• Azacitidine (Vidaza) 75 mg/m² IV once per day on days 1 to 7

28-day cycles

References

1. AZA-JMML-001: Niemeyer CM, Flotho C, Lipka DB, Starý J, Rössig C, Baruchel A, Klingebiel T, Micalizzi C, Michel G, Nysom K, Rives S, Schmugge Liner M, Zecca M, Schönung M, Baumann I, Nöllke P, Benettaib B, Biserna N, Poon J, Simcock M, Patturajan M, Menezes D, Gaudy A, van den Heuvel-Eibrink MM, Locatelli F. Response to upfront azacitidine in juvenile myelomonocytic leukemia in the AZA-JMML-001 trial. Blood Adv. 2021 Jul 27;5(14):2901-2908. link to original article link to PMC article PubMed NCT02447666